126 related articles for article (PubMed ID: 31622598)
1. YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways.
Suzuki H; Boki H; Kamijo H; Nakajima R; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S; Miyagaki T
J Invest Dermatol; 2020 Apr; 140(4):860-868.e3. PubMed ID: 31622598
[TBL] [Abstract][Full Text] [Related]
2. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
3. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.
Wu J; Wood GS
JAMA Dermatol; 2018 Oct; 154(10):1191-1198. PubMed ID: 30167641
[TBL] [Abstract][Full Text] [Related]
6. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778
[TBL] [Abstract][Full Text] [Related]
9. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
[TBL] [Abstract][Full Text] [Related]
10. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
[TBL] [Abstract][Full Text] [Related]
12. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
[TBL] [Abstract][Full Text] [Related]
13. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway.
Kuttikrishnan S; Masoodi T; Ahmad F; Sher G; Prabhu KS; Mateo JM; Buddenkotte J; El-Elimat T; Oberlies NH; Pearce CJ; Bhat AA; Alali FQ; Steinhoff M; Uddin S
J Dermatol Sci; 2023 Nov; 112(2):83-91. PubMed ID: 37865581
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.
Geskin LJ; Viragova S; Stolz DB; Fuschiotti P
Blood; 2015 Apr; 125(18):2798-805. PubMed ID: 25628470
[TBL] [Abstract][Full Text] [Related]
16. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.
Kodigepalli KM; Li M; Liu SL; Wu L
Cell Cycle; 2017 Jan; 16(2):179-188. PubMed ID: 27929746
[TBL] [Abstract][Full Text] [Related]
17. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
18. Targeting Phosphorylation of p21-activated Kinase 1 at Thr423 Induces Cell Cycle Arrest and Apoptosis in Cutaneous T-cell Lymphoma Cells.
Wang Y; Li W; Zhang Q; Gu X; He X; Men Y; Zhang C
Acta Derm Venereol; 2019 Oct; 99(11):1022-1028. PubMed ID: 31304555
[TBL] [Abstract][Full Text] [Related]
19. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas.
Sarris AH; Daliani D; Ulmer R; Crow M; Broxmeyer HE; Reiss M; Karasavvas N; Zelenetz AD; Pugh W; Cabanillas F; Deisseroth AB; Duvic M
Clin Cancer Res; 1997 Feb; 3(2):169-77. PubMed ID: 9815669
[TBL] [Abstract][Full Text] [Related]
20. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
